. 2014 Jan;58(1):1–10. doi: 10.1128/AAC.01790-12

TABLE 4.

Relation between ex vivo drug susceptibility at baseline and treatment outcome at day 42

Ex vivo agent tested pretreatment	Treatment	Treatment success		Recrudescence^a
Ex vivo agent tested pretreatment	Treatment	No. of tested ex vivo isolates	IC₅₀ ± SE (nM)	No. of tested ex vivo isolates	IC₅₀ ± SE (nM)
DEAQ	ASAQ	27	21.3 ± 2.7	8	31.8 ± 9.3
LUM	AL	32	15.1 ± 2.1	2	9.6 ± 3.4
DHA	ASAQ or AL	56	4.2 ± 0.4	9	3.6 ± 0.7
PYR	SP	1	1,001	13	7,390 ± 2,340

Recrudescence defined by msp1 and msp2 analyses.